HER2− positive (HER2+) tumors are very heterogeneous, and in many cases, the overexpression of HER2 is associated with the loss of both ER and PR expression, but for 10% of breast cancers, both ER and HER2 are co-expressed [11]. Here, ERBB2 is linked to breast carcinoma.